- Home
- ISRG vs BMY Comparison
ISRG vs BMY Comparison
Compare ISRG & BMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ISRG | BMY |
|---|---|---|
| Founded | 1995 | 1887 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 132.0B | 113.5B |
| IPO Year | 1998 | 2006 |
Fundamental Metrics
Financial Performance| Metric | ISRG | BMY |
|---|---|---|
| Price | $371.00 | $63.47 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 19 | 15 |
| Target Price | ★ $591.32 | $61.73 |
| AVG Volume (30 Days) | 2.1M | ★ 7.3M |
| Earning Date | 04-21-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 4.38% |
| EPS Growth | 22.59 | ★ 178.46 |
| EPS | ★ 4.57 | 2.93 |
| Revenue | $10,064,700,000.00 | ★ $48,194,000,000.00 |
| Revenue This Year | $16.64 | N/A |
| Revenue Next Year | $13.91 | N/A |
| P/E Ratio | $77.30 | ★ $21.98 |
| Revenue Growth | ★ 20.51 | N/A |
| 52 Week Low | $328.57 | $42.52 |
| 52 Week High | $603.88 | $68.64 |
Technical Indicators
Market Signals| Indicator | ISRG | BMY |
|---|---|---|
| Relative Strength Index (RSI) | 42.60 | 43.44 |
| Support Level | $328.57 | $63.00 |
| Resistance Level | $382.41 | $68.37 |
| Average True Range (ATR) | 10.70 | 1.27 |
| MACD | -2.08 | -0.56 |
| Stochastic Oscillator | 39.89 | 4.47 |
Price Performance
Historical ComparisonAbout ISRG Intuitive Surgical Inc.
Intuitive develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed more than 10,000 da Vinci systems in hospitals worldwide, with more than 6,000 installations in the US and a growing number in emerging markets.
About BMY Bristol-Myers Squibb Company
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.